What is William Blair's Estimate for Amgen Q4 Earnings?

Amgen Inc. (NASDAQ:AMGN - Free Report) - Equities researchers at William Blair issued their Q4 2026 earnings per share (EPS) estimates for Amgen in a research report issued to clients and investors on Wednesday, March 5th. William Blair analyst M. Phipps forecasts that the medical research company will post earnings per share of $4.77 for the quarter. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Several other brokerages have also recently weighed in on AMGN. Redburn Partners decreased their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Citigroup reaffirmed a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Wolfe Research assumed coverage on shares of Amgen in a research report on Friday, November 15th. They set a "peer perform" rating for the company. Royal Bank of Canada reaffirmed an "outperform" rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, Bank of America raised their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a research report on Wednesday, March 5th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amgen presently has a consensus rating of "Hold" and an average target price of $314.04.

Amgen Trading Down 0.0 %

Shares of Amgen stock traded down $0.06 on Monday, hitting $312.44. 1,326,337 shares of the company's stock traded hands, compared to its average volume of 3,170,854. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen has a one year low of $253.30 and a one year high of $346.85. The firm's 50-day moving average price is $289.70 and its two-hundred day moving average price is $299.52. The stock has a market capitalization of $167.84 billion, a PE ratio of 41.37, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping analysts' consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Capital Performance Advisors LLP bought a new stake in Amgen during the third quarter worth approximately $25,000. Centricity Wealth Management LLC acquired a new position in Amgen during the 4th quarter valued at $25,000. Pinney & Scofield Inc. bought a new position in Amgen in the fourth quarter worth $26,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the third quarter valued at $29,000. Finally, Ritter Daniher Financial Advisory LLC DE increased its holdings in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after purchasing an additional 51 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 in the last quarter. 0.69% of the stock is currently owned by company insiders.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.05%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.